The SuperHuman library contains over 5,000 hits against each of the 26 Distributed Bio targets in immunology and neurodegeneration.

The new agreement clears the Roche subsidiary to test its Tecentriq in combination with Syndax’s entinostat in a subset of breast cancer patients.

BioNTech will work with Scancell to discover and characterize T cell receptors and has an option to form a license agreement for the therapeutics.

The revised deal returns full global control of the ATTR amyloidosis drug to Alnylam and sees Sanofi obtain worldwide rights to fitusiran.

Pfizer dumped the drug after failing to find signs of efficacy in a phase 1 brain cancer trial, but iTeos thinks it has a future.

Next year will be a busy time for the European Medicines Agency as it looks to complete its move to Amsterdam.

Will this year’s resurgence be sustained in 2018 in the face of a more uncertain environment?

While 2016 was a year of cancelled and low-end IPOs, 2017 was a year marked by IPO momentum.